The MARIPOSA trial (NCT04487080) is a global study across 27 countries which will compare the first-line combination of amivantamab and lazertinib against the FDA-approved treatment of osimertinib monotherapy in NSCLC patients that harbor classical EGFR mutations [90]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.